Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis
Cerebrovascular biomarkers linked to amyloid beta (Aβ) in Alzheimer's disease (AD). White matter hyperintensities and cerebral microbleeds reliably predict Aβ-PET positivity. Relationships with Aβ-PET vary by cognitive stage. Novel accessible model predicts Aβ-PET status. Study supports multimodal diagnostic approaches.
Authors
- Zachary J. Kunicki (ORCID: https://orcid.org/0000-0002-3466-7589)
- James L. Rudolph
- Masood Manoochehri (ORCID: https://orcid.org/0000-0001-5818-180X)
- Edward D. Huey (ORCID: https://orcid.org/0000-0002-8295-5884)
- Sheina Emrani
- Matthew D. Howe (ORCID: https://orcid.org/0000-0002-6373-1535)
- Stephen P. Salloway
- Megan R. Caruso
- Hwamee Oh (ORCID: https://orcid.org/0000-0003-1156-5704)
Institutions
- Brown University (US)
- Butler Hospital (US)
- Providence VA Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/alz.14207
- Citations
- 1
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Alzheimer's Drug Discovery Foundation
- Eli Lilly and Company
- Biogen
- BioClinica
- Novartis Pharmaceuticals Corporation
- Takeda Pharmaceutical Company
- Fujirebio US
- Servier
- National Institutes of Health
- Genentech
- GE Healthcare
- Canadian Institutes of Health Research
- National Institute on Aging
- National Institute of Mental Health
- National Institute of Biomedical Imaging and Bioengineering